Home / Resources / Gene, Cell, + RNA Therapy Landscape Q4 2023 Report

Gene, Cell, + RNA Therapy Landscape Q4 2023 Report

Report
Clinical
ASGCT Citeline Q4 2023 Report

In Q4, the number of gene therapies in Phase III clinical trials grew by 10%, the first quarterly increase of that type since Q3 2022. Across the pipeline in 2023, RNA therapies had the largest number of approvals.

Related products
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape
Professional using a laptop device to access Trialtrove for trial insights and strategy.
Trialtrove
The go-to resource for informing clinical trial strategy, design and execution
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline

Related resources

Clinical-resource-ISCT Report_resource-card-thumbnail
JUN 01, 2023
Report
Clinical

Cell and Gene Therapy Global Regulatory Report

The first Cell and Gene Therapy Regulatory Report from Citeline and ISCT provides a global overview of the cell and gene therapy landscape.

CGT Development Is Booming_resource-card-thumbnail
NOV 22, 2023
Article
Commercial

CGT Development Is Booming, but Manufacturing Workforce Must Keep Up

Due to unprecedented growth in the development of cell and gene therapies, there is high demand for certain workforce roles.

ASGCT Citeline Q3 2023 Report_resource-card-thumbnail
OCT 01, 2023
Report
Commercial

Gene, Cell, + RNA Therapy Landscape Q3 2023 Report

Q3 2023 saw 3,866 therapies in development; 53% of those were gene therapies, 25% RNA therapies, and 22% non-genetically modified cell therapies.

View all resources